Clinical trials: Solid Organ Transplant
Transplantation Infection, Kidney Transplant; Complications
Intestinal Microbiome Dynamics in Solid Organ and Stem Cell Transplant Recipients
This is a pilot study designed to investigate the alterations in the gut microbiome that occur during the course of kidney transplantation, liver transplantation, allogeneic hematopoietic stem cells and mesenchymal stem cells…
- Conditions
- Transplantation Infection, Kidney Transplant; Complications, Stem Cell Transplant Complications, Liver Transplant; Complications
- Trial name
- NCT04281797
- Testing
- Intestinal microbiome new generation sequencing
- Where
- Belarus
- Volunteers
- 90 people
- Sponsor
- Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
While hematopoietic stem cell transplant (HSCT) is an effective therapy, graft versus host disease (GVHD) is the most significant complication after HSCT.
- Conditions
- Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant
- Trial name
- NCT05121142
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Solid Organ Transplant Complications, Solid Organ Transplant Recipients
Phase I Trial on the Safety of Delayed Infusion of a Naïve T Cell-Depleted Hematopoietic Graft With Memory T Cells in Solid Organ Transplant Recipients
The goal of this clinical trial is to evaluate the safety and feasibility of inducing hematopoietic mixed chimerism to promote immune tolerance and potentially reduce the need for lifelong immunosuppression in pediatric and adult…
- Conditions
- Solid Organ Transplant Complications, Solid Organ Transplant Recipients, Solid Organ Transplant Rejection
- Trial name
- DUALGRAFT (NCT06997471)
- Testing
- Investigational cellular therapy consisting on a HSCT using a graft enriched in CD34+, depleted of naïve T-lymphocytes and supplemented with memory lymphocytes
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Francisco Hernández Oliveros
Gastroenteritis Norovirus
NNITS-Nitazoxanide for Norovirus in Transplant Patients Study
This is a phase 2 multi-center, double-blind, placebo-controlled study of the efficacy and safety of nitazoxanide for the treatment of solid organ and hematopoietic stem cell transplant recipients with symptomatic diarrhea due to…
- Trial name
- NCT03395405
- Testing
- Nitazoxanide
- Where
- 12 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
CMV Infection, EBV
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
To assess the safety and biological efficacy of therapeutically administered most closely HLA-matched third party donor-derived specific cytotoxic T lymphocytes (CTLs) targeting cytomegalovirus (CMV) or Adenovirus (Adv) or…
- Conditions
- CMV Infection, EBV, Adenovirus
- Trial name
- R3ACT (NCT02779439)
- Testing
- Virus specific CTLs
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Sydney
Solid Organ Transplant Complications
Washed Microbiota Transplantation in Solid Organ Transplantation
Solid organ transplantation (SOT), an alternative therapy for end-stage diseases, offers increased longevity and better quantity of life.
- Trial name
- NCT06708676
- Testing
- Washed Microbiota Transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Medication Adherence, Liver Transplantation
A Study of mDOT for Immunosuppressant Adherence in Solid Organ Transplant Recipients
In solid organ transplant recipients, poor adherence to immunosuppressant medications carries the risk of graft rejection (needing a new transplant), post-transplant complications, and increased healthcare costs.
- Conditions
- Medication Adherence, Liver Transplantation, Kidney Transplantation
- Trial name
- NCT04587024
- Testing
- mHealth intervention, standard of care
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Johns Hopkins University
Measles
Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients
Measles is a vaccine-preventable disease, which can be life-threatening in immunosuppressed children. Currently, measles vaccine is not recommended in pediatric orthotopic liver transplant recipients, because it is a…
- Trial name
- MMRinOLT (NCT01770119)
- Testing
- MMR vaccination
- Where
- Switzerland
- Volunteers
- 90 people
- Sponsor
- Klara M. Pósfay Barbe
Influenza
Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK
This study aims to assess the risk of solid organ transplant (SOT) rejection following vaccination with Pandemrix™ and/ or seasonal influenza vaccination.
- Trial name
- NCT01715792
- Testing
- Data collection
- Where
- United Kingdom
- Volunteers
- 587 people
- Sponsor
- GlaxoSmithKline
Organ Transplantation
Perceived Barriers to Patient Adherence After Pediatric Solid Organ Transplantation
In this study, doctors will observe how and when pediatric patients who have received a solid organ transplant take their prescribed medication, and determining if there are reasons that keep these patients from taking all of…
- Trial name
- NCT01370746
- Where
- 15 sites in United States
- Volunteers
- 502 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunocompromised Host, Organ Transplantation
Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
Background: Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression End-stage renal disease…
- Conditions
- Immunocompromised Host, Organ Transplantation, Cancer
- Trial name
- NCT00904579
- Where
- 9 sites in United States
- Volunteers
- 19,929,901 people
- Sponsor
- National Cancer Institute (NCI)
Infection in Solid Organ Transplant Recipients, Complications of Organ Transplant
Respiratory Viral Infections in Pediatric Transplantation
A retrospective cohort of solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients will be assembled to determine the incidence of respiratory viral infections diagnosed during an inpatient admission…
- Conditions
- Infection in Solid Organ Transplant Recipients, Complications of Organ Transplant, Respiratory Viral Infection
- Trial name
- NCT02260596
- Where
- United States
- Volunteers
- 2,669 people
- Sponsor
- Duke University
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus, Donor, Solid Organ Transplantation Recipient
- Trial name
- NCT03665675
- Testing
- Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes, Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sumithira Vasu
Kidney Transplantation
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
Nonadherence to immunosuppression is a leading cause of late graft rejection, chronic rejection and graft failure and it is regarded as a preventable cause of graft loss after solid organ transplantation.
- Trial name
- PRIMA (NCT01905514)
- Testing
- internet mobile application
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Seoul National University Hospital
Solid Organ Transplant
Transition From Hospital to Home in Solid Organ Transplant (SOT)
The aim of this study is to determine the influences of discharge teaching and care coordination on how ready a parent is to take their child home from the hospital after a solid organ (kidney, heart and liver) transplant.
- Trial name
- NCT00907023
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Medical College of Wisconsin
Solid Organ Transplant Recipients, Autoimmune Diseases
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
DESIGN Observational epidemiological study AIMS - To determine: 1. The proportion of immunosuppressed people who have detectable SARS-CoV-2 antibodies following a primary vaccine course (3 doses), and the demographic, disease…
- Conditions
- Solid Organ Transplant Recipients, Autoimmune Diseases, Haematological Malignancies
- Trial name
- MELODY (NCT05148806)
- Testing
- self-administered lateral flow assays
- Where
- 4 sites in United Kingdom
- Volunteers
- 28,411 people
- Sponsor
- Imperial College London
HIV Positive, Organ Transplant Recipient
Transplantation and the Use of Raltegravir in HIV-Infected Patients
Raltegravir (RAL) is a preferred option for initial antiretroviral therapy in the most recent HIV Treatment Guidelines and is emerging as a popular choice for use in the specialized population of HIV-infected patients being…
- Conditions
- HIV Positive, Organ Transplant Recipient, Active Wait Listing for Organ Transplant
- Trial name
- NCT01793467
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Duke University
EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
This pilot phase II trial studies how well rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation…
- Conditions
- EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder
- Trial name
- NCT02900976
- Testing
- Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab
- Where
- 38 sites in United States
- Volunteers
- 18 people
- Sponsor
- Children's Oncology Group
Solid Organ Transplant Rejection, COVID-19
AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience
The utilization of AlloSure to help guide immunosuppression management in solid organ transplant recipients diagnosed with COVID-19
- Trial name
- Al-COVE (NCT04341103)
- Volunteers
- 500 people
- Sponsor
- CareDx